WHO Pharmaceuticals Newsletter 1998, No. 03&04
(1998; 18 pages)
Índice de contenido
Cerrar esta carpetaRegulatory actions
Ver el documentoAluminium in total parenteral nutrition - labelling requirements & warning
Ver el documentoAstemizole - warning concerning cardiovascular adverse events
Ver el documentoBromfenac - warning label: liver damage
Ver el documentoCarbamazepine - warning concerning precipitation
Ver el documentoChlormezanone - withdrawn
Ver el documentoCounterfeit drugs - warning to the public
Ver el documentoDietary supplement "Sleeping Buddha" - warning concerning estazolam content
Ver el documentoFenfluramine - withdrawn
Ver el documentoHuman dura mater (freeze-dried) - restrictive measures
Ver el documentoIsotretinoin - psychiatric adverse effects
Ver el documentoPyrithione zinc (Skin-CapR) - withdrawn
Ver el documentoSertindole - approval application withdrawn
Ver el documentoTerfenadine - additional drug interactions
Ver el documentoTerfenadine - withdrawn following approval of fexofenadine
Abrir esta carpeta y ver su contenidoDrug surveillance
Abrir esta carpeta y ver su contenidoNew developments
Ver el documentoRecent approvals
Abrir esta carpeta y ver su contenidoMedical devices
Abrir esta carpeta y ver su contenidoGeneral information
Abrir esta carpeta y ver su contenidoVeterinary medicine
 

Pyrithione zinc (Skin-CapR) - withdrawn

United Arab Emirates. The Ministry of Health has withdrawn the marketing approval for pyrithione zinc (Skin-CapR), which is indicated for the treatment of dandruff or psoriasis. This follows concern raised by the FDA and Canada after closer analysis of the product revealed that it contained an (unlabelled) prescription strength corticosteroid (clobetasol).

[See also DRS Alert No. 64 of 19 September 1997]

Reference: UAE Ministry of Health Drug Information Bulletin 1997 No. 3, p.2.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013